In addition, we found that a higher expression of BHLHE40-AS1 or BHLHE40 (these two genes are transcribed on opposite strands) was associated with a significantly decreased OS among TCGA ovarian cancer patients with a follow-up time >60 months (P = 0.034, Fig. 3b). This evidence concerns the gene BHLHE40 and ovarian cancer.